NRX Pharmaceuticals, Inc. Costs and Expenses
NRX Pharmaceuticals, Inc. (NRXP) reported Costs and Expenses of $7.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-14
- NRX Pharmaceuticals, Inc. costs and expenses for the quarter ending 2026-06-30 was $7.61M, a 103.91% increase year-over-year.
- NRX Pharmaceuticals, Inc. costs and expenses for the quarter ending 2026-03-31 was $5.81M, a 51.03% increase year-over-year.
- NRX Pharmaceuticals, Inc. costs and expenses for the quarter ending 2025-12-31 was $5.61M, a 130.55% increase year-over-year.
- NRX Pharmaceuticals, Inc. costs and expenses for the quarter ending 2025-09-30 was $4.27M, a 41.16% increase year-over-year.
- NRX Pharmaceuticals, Inc. costs and expenses for fiscal 2025 was $17.45M, a 5.69% decline from fiscal 2024.
- NRX Pharmaceuticals, Inc. costs and expenses for fiscal 2024 was $18.50M.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.61M 10-Q · filed 2026-08-14 | $13.42M 10-Q · filed 2026-08-14 | $19.02M derived: sum of 3 quarters · filed 2026-08-14 | $23.29M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $5.81M 10-Q · filed 2026-05-15 | $11.42M derived: sum of 2 quarters · filed 2026-05-15 | $15.68M derived: sum of 3 quarters · filed 2026-05-15 | $19.41M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $5.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $9.87M derived: sum of 2 quarters · filed 2026-03-23 | $13.60M derived: sum of 3 quarters · filed 2026-08-14 | $17.45M 10-K · filed 2026-03-23 |
| 2025-09-30 | $4.27M 10-Q · filed 2025-11-14 | $8.00M derived: sum of 2 quarters · filed 2026-08-14 | $11.84M 10-Q · filed 2025-11-14 | $14.28M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $3.73M 10-Q · filed 2026-08-14 | $7.58M 10-Q · filed 2026-08-14 | $10.01M derived: sum of 3 quarters · filed 2026-08-14 | $13.03M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $3.85M 10-Q · filed 2026-05-15 | $6.28M derived: sum of 2 quarters · filed 2026-05-15 | $9.30M derived: sum of 3 quarters · filed 2026-05-15 | |
| 2024-12-31 | $2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $5.45M derived: sum of 2 quarters · filed 2026-03-23 | $18.50M 10-K · filed 2026-03-23 | |
| 2024-09-30 | $3.02M 10-Q · filed 2025-11-14 | $16.07M 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |